革命性的人工晶状体– InFo Instant Focus© – 具备更大屈光度范围的型号现已上市
瑞士纳沙泰尔 — (美国商业资讯) — Swiss Advanced Vision公司(SAV-IOL SA – www.sav-iol.com)宣布,具备更宽屈光度范围的人工晶状体(IOL) InFo Instant Focus©现已上市,该型号适用于晶状体摘除后的白内障治疗。 Smart News Releases(智能新闻稿)是一个多媒体平台。在此处查看完整新闻稿:...
View Article革命的眼内レンズのInFo Instant Focus©をより広範な度数範囲で提供
スイス・ヌーシャテル (ビジネスワイヤ) — Swiss Advanced Vision (SAV-IOL SA – www.sav-iol.com)は、水晶体摘出後の白内障治療が適応の眼内レンズ(IOL)であるInFo Instant Focus©をより広範な度数範囲で提供できるようになったと発表しました。 このSmart News...
View ArticleOra®がデビッド・ホランダー医師(M.D.、M.B.A.)を最高医学責任者(CMO)に任命
ボストン (ビジネスワイヤ) — 眼科用医薬品・医療機器の開発における世界一流パートナーのOra,...
View ArticleOra®任命David Hollander, M.D., M.B.A.为首席医学官
波士顿 (美国商业资讯) — 世界领先的眼科药品及器械开发伙伴Ora, Inc.今天宣布任命David A. Hollander, M.D., M.B.A.为首席医学官兼高级副总裁。Hollander博士的最近职务是Allergan®的治疗领域负责人兼临床开发副总裁,负责前段眼科和消费者眼护理的全球战略和临床开发项目。 Ora总裁兼首席执行官Stuart B....
View Articleサルタリス・メディカル・デバイシズによる滲出型AMD脈絡膜厚測定研究の結果がARVO 2016で発表される
シアトル (ビジネスワイヤ) — サルタリス・メディカル・デバイシズ・インク (SalutarisMD®)による滲出型加齢黄斑変性(滲出型AMD)脈絡膜厚測定研究 (DOCS)の結果が本日、視覚・眼科学研究協会(ARVO)年次総会における2件の発表で取り上げられました。 1件目のポスター発表はDr. Kamaljit...
View ArticleAcucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic...
SEATTLE Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of...
View ArticleHoya Reports Fourth Quarter Results; Achieves Record Annual Sales and Profit
TOKYO HOYA Corporation (TOKYO:7741) today announced financial results for the fourth quarter and full-year ended March 31, 2016. During the quarter, revenues decreased by 4.5% to 121,666 million yen...
View Articleサンバイオ、再生細胞薬SB623の網膜変性疾患用途特許を取得
米国カリフォルニア州マウンテンビュー (ビジネスワイヤ) — 再生細胞薬の開発・製造を手掛ける当社グループ(サンバイオ株式会社およびその子会社であるSanBio...
View ArticleSanBio Granted Key Patent in Treatment for Macular Degeneration
MOUNTAIN VIEW, Calif. SanBio, Inc., a scientific leader in regenerative medicine, today announced it has been granted a key patent by the United States Patent and Trademark Office (USPTO) covering...
View ArticleAcucela Announces Top-Line Results from Phase 2b/3 Clinical Trial of Emixustat
SEATTLE Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of...
View Article脳梗塞を対象とした米国フェーズ1/2a試験の投与後12ヵ月経過時の結果をStroke誌に発表
米国カリフォルニア州マウンテンビュー (ビジネスワイヤ)―神経系疾患を対象に再生細胞薬の開発・製造を手掛ける当社グループ(サンバイオ株式会社及びその子会社であるSanBio, Inc.) は、今般、American Heart...
View ArticlePhotometrics Launches Next Generation Scientific CMOS Camera with 95 Percent...
TUCSON, Ariz. Photometrics®, a manufacturer of high-performance scientific cameras for life science applications, and Gpixel Inc., a company specializing in high-performance CMOS image sensors,...
View ArticleLeading Augmented and Mixed Reality Optical Display Developer Lumus Ltd....
RECHOVOT, Israel Lumus Ltd., a leading developer of high-end transparent near-to-eye displays for augmented reality (AR), mixed reality (MR) and smart eyewear, announced today that it has received...
View ArticleAnnouncement Regarding the News Coverage Concerning an Inquiry on Trades of...
SEATTLE Acucela Inc. (Tokyo:4589) (the “Company”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of...
View ArticlePresbia to Participate in the 2016 Australasian Society of Cataract and...
DUBLIN Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced that it will participate in the 20th Annual Australasian Society of Cataract and...
View ArticleCigna Launches Brand Campaign for International Markets Based on Real Stories...
HONG KONG Cigna has unveiled its first ever regional brand campaign for key international markets, designed to showcase the company’s capabilities and the solutions it delivers for customers. The...
View ArticleDr. Oh Has Succeeded in the Research of LASEK on Reduction of Eye Damage
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 SEOUL, South Korea Dr. Oh Jung Woo of EOS eye center released a surprising study that improves the safety of existing vision correction...
View ArticleSecond Sight Announces Two Exclusive Distribution Agreements to Bring the...
SYLMAR, Calif. Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to restore some useful...
View ArticleHoya Reports First Quarter Financial Results
TOKYO HOYA Corporation (TOKYO: 7741) today announced financial results for the first quarter ended June 30, 2016. During the quarter, revenues totaled 115,165 million yen, representing a decline of...
View ArticleAcucela Announces Official Name of Acucela Japan as Kubota Pharmaceutical...
SEATTLE Acucela Inc. (Tokyo: 4589) (the “Company”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of...
View Article